We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
3D Systems (DDD) to Expand VSP Bolus Distribution With Klarity
Read MoreHide Full Article
3D Systems (DDD - Free Report) recently revealed that it has partnered with the medical products maker, Klarity, to expand the distribution of its VSP Bolus solution. Under the terms of the deal, Klarity will add VSP Bolus to its patient-specific 3D-printed products, Klarity Prints.
Powered by 3D Systems, Klarity Prints is a service-based line of 3D-printed radiotherapy accessories that does not need specialized hardware or software.
The VSP Bolus, which is approved by the U.S. Food and Drug Administration, is designed as a patient-specific biocompatible 3D-printed material aimed at enhancing the patient's experience by contouring their anatomy. These boluses are crafted to eliminate the need for clinicians to work with complex software and hardware, thereby improving patient care, comfort and reducing technician time.
This innovative product will be accessible to radiotherapy clinics across the United States and Canada through Klarity's distribution network. Interested clinics can get in touch with Klarity's Account Managers to receive the patient-specific bolus within a few days.
3D Systems Benefits From Robust Portfolio
Additive manufacturing is gaining traction among larger industries seeking economically viable solutions. 3D Systems, recognizing its position as the largest among all additive manufacturing companies, is actively pursuing scalability.
The company is also entering into the fields of biotechnology, metal additive manufacturing and large-format pellet extrusion printing through partnerships with Theradaptive, Oerlikon AM and SWANY Co. Ltd., respectively.
DDD has inked a partnership in the regenerative medicine segment where it collaborated with United Therapeutics (UTHR - Free Report) . The companies aim to create highly intricate products, including 3D-printed lungs.
United Therapeutics, a public benefit corporation, is involved in the pursuit of organ manufacturing. Recently, UTHR successfully transplanted a genetically engineered heart, known as Xenoheart, into a living person.
3D Systems also operates in the healthcare sector and it is among the big players in the 3D printed orthodontics segment. With the booming 3D printing industry, DDD’s focus on this market presents a favorable long-term opportunity.
Zacks Rank
3D Systems currently carries a Zacks Rank #2 (Buy), while United Therapeutics carries a Zacks Rank #3 (Hold). Shares of DDD and UTHR have plunged 40.5% and 16.4% year to date, respectively. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Other Key Picks
Some other top-ranked stocks from the broader Computer and Technology sector are NVIDIA Corporation (NVDA - Free Report) and Asure Software (ASUR - Free Report) .
The Zacks Consensus Estimate for NVIDIA's third-quarter fiscal 2024 earnings has been revised upward by 8 cents to $3.32 per share in the past 30 days. For fiscal 2024, earnings estimates have increased by 21 cents to $10.67 per share in the past 30 days.
NVIDIA’s earnings beat the Zacks Consensus Estimate thrice in the preceding four quarters, while missing on one occasion, the average surprise being 9.8%. Shares of NVDA have surged 190.6% year to date.
The Zacks Consensus Estimate for Asure Software’s third-quarter 2023 earnings has been revised to a penny northward to 6 cents per share over the past 30 days. For 2023, earnings estimates have moved 3 cents north to 54 cents per share in the past 30 days.
Asure's earnings beat the Zacks Consensus Estimate in each of the preceding four quarters, the average surprise being 676.4%. Shares of ASUR have lost 0.9% year to date.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
3D Systems (DDD) to Expand VSP Bolus Distribution With Klarity
3D Systems (DDD - Free Report) recently revealed that it has partnered with the medical products maker, Klarity, to expand the distribution of its VSP Bolus solution. Under the terms of the deal, Klarity will add VSP Bolus to its patient-specific 3D-printed products, Klarity Prints.
Powered by 3D Systems, Klarity Prints is a service-based line of 3D-printed radiotherapy accessories that does not need specialized hardware or software.
The VSP Bolus, which is approved by the U.S. Food and Drug Administration, is designed as a patient-specific biocompatible 3D-printed material aimed at enhancing the patient's experience by contouring their anatomy. These boluses are crafted to eliminate the need for clinicians to work with complex software and hardware, thereby improving patient care, comfort and reducing technician time.
3D Systems Corporation Price and Consensus
3D Systems Corporation price-consensus-chart | 3D Systems Corporation Quote
This innovative product will be accessible to radiotherapy clinics across the United States and Canada through Klarity's distribution network. Interested clinics can get in touch with Klarity's Account Managers to receive the patient-specific bolus within a few days.
3D Systems Benefits From Robust Portfolio
Additive manufacturing is gaining traction among larger industries seeking economically viable solutions. 3D Systems, recognizing its position as the largest among all additive manufacturing companies, is actively pursuing scalability.
The company is also entering into the fields of biotechnology, metal additive manufacturing and large-format pellet extrusion printing through partnerships with Theradaptive, Oerlikon AM and SWANY Co. Ltd., respectively.
DDD has inked a partnership in the regenerative medicine segment where it collaborated with United Therapeutics (UTHR - Free Report) . The companies aim to create highly intricate products, including 3D-printed lungs.
United Therapeutics, a public benefit corporation, is involved in the pursuit of organ manufacturing. Recently, UTHR successfully transplanted a genetically engineered heart, known as Xenoheart, into a living person.
3D Systems also operates in the healthcare sector and it is among the big players in the 3D printed orthodontics segment. With the booming 3D printing industry, DDD’s focus on this market presents a favorable long-term opportunity.
Zacks Rank
3D Systems currently carries a Zacks Rank #2 (Buy), while United Therapeutics carries a Zacks Rank #3 (Hold). Shares of DDD and UTHR have plunged 40.5% and 16.4% year to date, respectively. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Other Key Picks
Some other top-ranked stocks from the broader Computer and Technology sector are NVIDIA Corporation (NVDA - Free Report) and Asure Software (ASUR - Free Report) .
The Zacks Consensus Estimate for NVIDIA's third-quarter fiscal 2024 earnings has been revised upward by 8 cents to $3.32 per share in the past 30 days. For fiscal 2024, earnings estimates have increased by 21 cents to $10.67 per share in the past 30 days.
NVIDIA’s earnings beat the Zacks Consensus Estimate thrice in the preceding four quarters, while missing on one occasion, the average surprise being 9.8%. Shares of NVDA have surged 190.6% year to date.
The Zacks Consensus Estimate for Asure Software’s third-quarter 2023 earnings has been revised to a penny northward to 6 cents per share over the past 30 days. For 2023, earnings estimates have moved 3 cents north to 54 cents per share in the past 30 days.
Asure's earnings beat the Zacks Consensus Estimate in each of the preceding four quarters, the average surprise being 676.4%. Shares of ASUR have lost 0.9% year to date.